COVID-19 Antiviral and Treatment Candidates: Current Status
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Espano, Erica | - |
dc.contributor.author | Kim, Dajung | - |
dc.contributor.author | Kim, Jiyeon | - |
dc.contributor.author | Park, Song-Kyu | - |
dc.contributor.author | Kim, Jeong-Ki | - |
dc.date.accessioned | 2021-12-04T07:41:33Z | - |
dc.date.available | 2021-12-04T07:41:33Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-02 | - |
dc.identifier.issn | 1598-2629 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/129316 | - |
dc.description.abstract | The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 has severely impacted global health and economy. There is currently no effective approved treatment for COVID-19; although vaccines have been granted emergency use authorization in several countries, they are currently only administered to high-risk individuals, thereby leaving a gap in virus control measures. The scientific and clinical communities and drug manufacturers have collaborated to speed up the discovery of potential therapies for COVID-19 by taking advantage of currently approved drugs as well as investigatory agents in clinical trials. In this review, we stratified some of these candidates based on their potential targets in the progression of COVID-19 and discuss some of the results of ongoing clinical evaluations. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREA ASSOC IMMUNOLOGISTS | - |
dc.subject | CORONAVIRUS DISEASE 2019 | - |
dc.subject | HEPATITIS-C | - |
dc.subject | IN-VITRO | - |
dc.subject | CHIKUNGUNYA VIRUS | - |
dc.subject | OPEN-LABEL | - |
dc.subject | RIBAVIRIN | - |
dc.subject | MULTICENTER | - |
dc.subject | SARS | - |
dc.subject | INTERFERON-ALPHA-2B | - |
dc.subject | HYPERINFLAMMATION | - |
dc.title | COVID-19 Antiviral and Treatment Candidates: Current Status | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Song-Kyu | - |
dc.contributor.affiliatedAuthor | Kim, Jeong-Ki | - |
dc.identifier.doi | 10.4110/in.2021.21.e7 | - |
dc.identifier.scopusid | 2-s2.0-85102735984 | - |
dc.identifier.wosid | 000626257600007 | - |
dc.identifier.bibliographicCitation | IMMUNE NETWORK, v.21, no.1, pp.1 - 24 | - |
dc.relation.isPartOf | IMMUNE NETWORK | - |
dc.citation.title | IMMUNE NETWORK | - |
dc.citation.volume | 21 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 24 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002692716 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.subject.keywordPlus | CORONAVIRUS DISEASE 2019 | - |
dc.subject.keywordPlus | HEPATITIS-C | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | CHIKUNGUNYA VIRUS | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | RIBAVIRIN | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | SARS | - |
dc.subject.keywordPlus | INTERFERON-ALPHA-2B | - |
dc.subject.keywordPlus | HYPERINFLAMMATION | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | Severe acute respiratory syndrome coronavirus 2 | - |
dc.subject.keywordAuthor | Antiviral agents | - |
dc.subject.keywordAuthor | Immunotherapy | - |
dc.subject.keywordAuthor | Drug repositioning | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.